Concomitant cryoglobulinaemic vasculitis alongside ANCA-associated vasculitis: concurrence or coincidental individual occurrence

Jeong Yeop Whang; Jang Woo Ha; Jihye Chung; Yong-Beom Park; Jaewoo Song; Younhee Park; Sang-Won Lee

doi:10.3904/kjim.2025.094

Korean J Intern Med > Volume 41(5); 2026 > Article

Whang, Ha, Chung, Park, Song, Park, and Lee: Concomitant cryoglobulinaemic vasculitis alongside ANCA-associated vasculitis: concurrence or coincidental individual occurrence

Original Article

Rheumatology

The Korean Journal of Internal Medicine 2026;41(5):952-960.

Published online: September 1, 2026

DOI: https://doi.org/10.3904/kjim.2025.094

Concomitant cryoglobulinaemic vasculitis alongside ANCA-associated vasculitis: concurrence or coincidental individual occurrence

Jeong Yeop Whang^1,^*, Jang Woo Ha^2,^*, Jihye Chung³, Yong-Beom Park^3,⁴, Jaewoo Song⁵, Younhee Park⁵

, Sang-Won Lee^3,⁴

¹Department of Medicine, Yonsei University College of Medicine, Seoul, Korea

²Division of Rheumatology, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Korea

³Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea

⁴Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Korea

⁵Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea

Correspondence to: Sang-Won Lee, M.D., Ph.D., Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Korea, Tel: +82-2-2228-1987, Fax: +82-2-393-6884, E-mail: sangwonlee@yuhs.ac, https://orcid.org/0000-0002-8038-3341

Correspondence to: Younhee Park, M.D., Ph.D., Department of Laboratory Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea, Tel: +82-2-2228-2449, Fax: +82-2-2227-8353, E-mail: younheep@yuhs.ac, https://orcid.org/0000-0001-8458-1495

^*These authors contributed equally to this manuscript.

Received March 22, 2025 Revised May 10, 2025 Accepted April 3, 2026

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background/Aims

Cryoglobulinaemic vasculitis (CryoVas) and antineutrophil cytoplasmic antibody-associated vasculitis (AAV) share the common characteristic of being small vessel vasculitides but exhibit significant differences in pathologic findings. This study investigated the incidence rate of cryoglobulinaemia and the concurrence of AAV and CryoVas in AAV patients without chronic viral hepatitis or haematologic malignancies.

Methods

Among the 324 patients diagnosed with AAV, 136 with available cryoglobulin test results were included. Their clinical data were reviewed, and clinical and laboratory data, including AAV-specific indices at diagnosis, were recorded. Repeated cryoglobulinaemia was defined as cryoglobulin positivity in sera on at least two occasions separated by an interval of ≥ 12 weeks. The classification criteria for CryoVas were applied to all 136 patients with AAV.

Results

The median age of the patients was 61.0 years (50.0−69.0), and 41.2% were male patients. Of the 136 patients, 75, 31, and 30 were diagnosed with microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic GPA, respectively. Cryoglobulin was detected in sera of only two patients, yielding a detection rate of 1.5%. Both patients exhibited repeated cryoglobulinaemia and presented with red skin spots, constitutional symptoms, articular involvement, and vascular involvement; enabling their classification as having CryoVas alongside MPA. Additionally, one patient displayed peripheral neuropathy, reduced serum C4 levels, and rheumatoid factor positivity.

Conclusions

This study represents the first demonstration that the incidence rates of cryoglobulinaemia and CryoVas are 1.5% in patients with AAV without chronic viral hepatitis or haematologic malignancies.

Keywords: Cryoglobulins; Antibodies, antineutrophil cytoplasmic; Cryoglobulinemia; Vasculitis

Graphical abstract

INTRODUCTION

Cryoglobulin refers to a group of circulating immunoglobulins (Igs) that precipitate in vitro at temperatures below 37°C and may redissolve at ≥ 37°C. From a laboratory perspective, this term does not denote solely isolated or specified immunoglobulins targeting a defined series of antigens [1]. Cryoglobulinaemia is defined as a medical condition characterised by the presence of cryoglobulin in sera and is classified into three types according to the characteristics of the antibodies: type I, comprising monoclonal IgM, or monoclonal IgG; type II, comprising monoclonal IgM, and polyclonal IgG; and type III, comprising polyclonal IgM + polyclonal IgG. Types II and III are categorised as mixed cryoglobulinaemia due to their composition of varying mono- or polyclonal IgM and polyclonal IgG [1,2]. In most cases of mixed cryoglobulinaemia, rheumatoid factor (RF) constitutes the IgM fraction exhibiting binding affinity for the Fc fragment of IgG [3]. Type I cryoglobulinaemia is frequently associated with haematological diseases, whereas, type II and III are commonly linked to infectious and inflammatory conditions [1,2].

Most patients with cryoglobulinaemia remain asymptomatic; however, a small proportion may infrequently present with diverse systemic symptoms, including cryoglobulinaemic vasculitis (CryoVas) [4]. CryoVas, a small vessel vasculitis, is characterised by vasculitis with cryoglobulin immune deposits in capillaries, venules, or arterioles, and associated with cryoglobulins in sera [5]. This condition predominantly affects three major organ systems: the skin, kidneys, and peripheral nervous system [6,7]. By contrast, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is also a small vessel vasculitis, distinguished by fibrinoids in predominantly small vessels and occasionally medium-sized arteries, and is associated with ANCAs in sera [5]. Although AAV and CryoVas share similarities in the size of affected vessels, their histological features differ markedly. Unlike CryoVas, AAV primarily exhibits few or no immune deposits in affected tissues, a key feature distinguishing it from Cryo-Vas [8,9]. Consequently, simultaneous occurrence of AAV and CryoVas has been considered unlikely.

Nevertheless, the potential concurrence of AAV and Cryo-Vas warrants reconsideration for two reasons: AAV is an uncommon cause of cryoglobulinaemia [2], and the systemic involvement and clinical manifestations of the two vasculitides are notably similar [6,7,10–14]. To date, few reports have documented ANCA-positive patients with cryoglobulinaemia alongside underlying conditions such as viral hepatitis, or conversely, cryoglobulin-positive patients with AAV [15,16]. However, the concurrence of AAV and CryoVas, or the differentiation of their clinical features, has not been investigated in a substantial cohort of patients with AAV. Therefore, this study examined the incidence of cryoglobulinaemia and concurrence of CryoVas in 324 patients with AAV.

METHODS

Patients

In this study, medical records of 324 patients with AAV enrolled in the Severance Hospital ANCA-associated VasculitidEs (SHAVE) cohort were retrospectively reviewed. Patients were included based on the following criteria: i) initial classification of AAV was established at this hospital by rheumatologists between November 2005 and June 2024; ii) fulfilment of the 1990 American College of Rheumatology (ACR) classification criteria for eosinophilic granulomatosis with polyangiitis (EGPA), the 2007 European Medicine Agency algorithm for AAV, and the 2012 revised international Chapel Hill Consensus Conference nomenclature of vasculitides at diagnosis [5,10]; iii) fulfilment of the 2022 ACR/European Alliance of Associations for Rheumatology (EULAR) classification criteria for AAV at diagnosis [11–14]; iv) availability of well-documented medical records sufficient to collect clinical data at diagnosis; v) availability of the results of ANCA tests performed within 4 weeks before or at diagnosis [17,18]; vi) availability of the results of cryoglobulin tests performed at diagnosis, with additional results from repeated tests approximately 12 weeks later in cases of cryoglobulin-positive patients [6]; vii) follow-up duration of 6 months or longer after diagnosis; viii) absence of concomitant serious infectious diseases or malignancies at diagnosis (including no evidence of hepatitis B or hepatitis C viral infection) [11–13]; and ix) no history of immunosuppressive drug use within 4 weeks before diagnosis.

This study was approved by the Institutional Review Board (IRB) of Severance Hospital (Seoul, Korea; IRB No. 4-2020-1071), and conducted in accordance with the Declaration of Helsinki. Due to the retrospective design of the study and use of anonymised patient data, the requirement for written informed consent was waived.

Clinical data at diagnosis

Demographic including age, sex, body mass index (BMI), and smoking history were collected. AAV-related variables, such as AAV subtype, ANCA type and positivity, AAV-specific indices, and systemic manifestations, were reviewed. Myeloperoxidase (MPO)-ANCA and proteinase 3 (PR3)-ANCA were measured using an immunoassay, whereas, perinuclear (P)-ANCA and cytoplasmic (C)-ANCA were detected using an indirect immunofluorescence assay with ethanol fixation. According to the 2022 ACR/EULAR classification criteria for AAV, both MPO-ANCA/PR3-ANCA and P-ANCA/ C-ANCA were recognised as ANCA results [11–13]. AAV-specific indices included the Birmingham vasculitis activity score (BVAS), and the Five-factor score (FFS) at diagnosis [19,20]. Systemic manifestations were investigated based on the systemic items of BVAS [19]. The results of laboratory tests performed at diagnosis including erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels were also documented.

Detection of cryoglobulin

Whole blood was collected in a plain tube (without an anticoagulant), pre-warmed to 37°C, and immediately centrifuged at 3,500 rpm for 15 minutes at 37°C to separate the serum. The serum was then aliquoted into two tubes: one tube was stored in a refrigerator at 4°C, and the other was incubated at 37°C for 3 days. After this period, the tube stored at 4°C was examined for precipitate or gel formation, compared with the tube maintained at 37°C. The tube from the refrigerator was then returned to the 37°C incubator, and the dissolution of any precipitate was monitored upon warming. Repeated cryoglobulinaemia was defined as cryoglobulin positive in sera on at least two occasions separated by an interval of ≥12 weeks [6,7].

Classification of CryoVas

CryoVas was identified and classified according to the established criteria. Two entry requirements must be met: (i) at least two of the three items (questionnaire, clinical, and laboratory items) must be satisfied and (ii) cryoglobulin must be detected in sera on two separate occasions with an interval of ≥ 12 weeks. The questionnaire item comprised two sub-items regarding skin lesions and a sub-item regarding viral hepatitis, in which at least two of the three sub-items are needed to meet this item. The clinical item includes constitutional, articular, vascular, and neurological sub-items, with at least three necessary to meet this item. The laboratory item encompasses reduced C4 levels, RF positivity, and serum M component positivity, with at least two required to satisfy this item [3,6,7].

Statistical analyses

All statistical analyses were performed using the SPSS version 26 (IBM Corporation, Armonk, NY, USA) for Windows (Microsoft Corporation, Redmond, WA, USA). Continuous and categorical variables were expressed as medians (25 and 75 percentiles), and numbers (percentages).

RESULTS

Selection of patients

Of the 324 patients with AAV, 188 were excluded due to the absence of cryoglobulin testing. Consequently, 136 patients with available cryoglobulin test results were included, and their clinical data were reviewed (Fig. 1).

Characteristics of patients at diagnosis

Among the 136 patients with cryoglobulin test results, the median age of the patients was 61.0 years (50.0−69.0), and 41.2% were men. The median BMI was 22.6 kg/m² (20.8−24.8), and only two patients had a history of smoking. Of these 136 patients, 75, 31, and 30 were diagnosed with microscopic polyangiitis (MPA), GPA, and EGPA, respectively. The detection rates of MPO-ANCA (or P-ANCA), and PR3-ANCA (or C-ANCA) were 74.3%, and 14.7%, respectively. The median BVAS was 11.0 (6.0−17.0), and the median FFS was 1.0 (0−2.0). The most frequently observed clinical manifestation was pulmonary manifestation (70.6%), followed by renal manifestation (55.1%). Additionally, the median ESR and CRP levels were measured as 58.0 (19.0−96.0) mm/h, and 8.5 (1.4−48.2) mg/L, respectively (Table 1).

Cryoglobulin positivity

Cryoglobulin was detected in the sera of only two of the 136 patients, yielding a detection rate of 1.5% (Table 1).

Classification of CryoVas

The classification criteria for CryoVas were applied to AAV patients exhibiting repeated cryoglobulinaemia [6,7]. Patient #1, a female patient aged 65 years, demonstrated repeated cryoglobulinaemia. She was diagnosed with MPA based on MPO-ANCA positivity, histologically confirmed ANCA-associated glomerulonephritis (GN) and interstitial lung disease. She had red skin spots and experienced discoloration when they disappeared several times before or at diagnosis, which met the questionnaire item of CryoVas. She presented with fatigue, high fever, arthralgia, purpura in her lower extremities, and peripheral neuropathy at diagnosis, all of which met the clinical criteria for CryoVas. Additionally, the patient exhibited reduced C4 levels and RF positivity at diagnosis, meeting the laboratory criteria for CryoVas. Accordingly, patient #1 was classified as having CryoVas alongside MPA (Table 2). Patient #2, a female aged 75 years, also exhibited repeated cryoglobulinaemia. She was diagnosed with MPA based on MPO-ANCA positivity, ANCA-associated GN, and fibrotic lung alterations. She fulfilled the same questionnaire and clinical items as patient #1, except for the absence of peripheral neuropathy. No abnormal findings were observed in the laboratory sub-item. Consequently, patient #2 was also classified as having CryoVas alongside MPA (Table 2). Based on these findings, we conclude that the incidence rate of CryoVas in patients with AAV is 1.5%.

DISCUSSION

Given that AAV is an uncommon aetiology of cryoglobulinaemia and that both CryoVas and AAV are classified as small vessel vasculitides despite differing histological features [1,2,5], CryoVas might reasonably be expected to develop in patients with AAV. Consequently, this study investigated the incidence of cryoglobulinaemia and the potential classification of CryoVas among patients with AAV without chronic viral hepatitis or haematologic malignancies. Several notable findings emerged. First, cryoglobulin was detected in the sera of two of the 136 patients with AAV, both exhibiting repeated cryoglobulinaemia, and these patients were classified as having CryoVas alongside AAV, yielding a detection rate of cryoglobulin and an incidence of CryoVas of 1.5%. Second, all patients with AAV exhibiting repeated cryoglobulinaemia met the criteria for CryoVas. Third, all patients classified as having concomitant CryoVas presented with purpuric skin lesions, constitutional (febrile) symptoms, and articular manifestations. Fourth, neurological manifestations and CryoVas-related laboratory findings varied between the two patients. We conclude that cryoglobulin can be detected in sera of patients with AAV and it may critically contribute to the classification of concomitant CryoVas.

The findings raise several critical considerations. The initial question concerns whether AAV or CryoVas primarily accounts for the observed clinical symptoms. Fever, arthralgia, and purpuric lesions in patients classified as having CryoVas alongside AAV play critical roles in the classification criteria for CryoVas [6]. At the same time, they also belong to the items of the BVAS used to assess AAV activity: general and cutaneous manifestations [19]. Nonetheless, these symptoms were deemed more likely associated with CryoVas than AAV, as general and cutaneous manifestations were observed in only 33.8% and 16.9% of patients with AAV, respectively, compared with 100.0% of those with CryoVas in this study. Peripheral neuropathy, observed in only one patient classified as having CryoVas alongside AAV, could not be definitely attributed to either condition, given its prevalence in both AAV and CryoVas [21]. Had a nerve biopsy been performed-similar to the kidney biopsy confirming ANCA-associated GN-it might have aided in distinguishing between the two diseases [22–24]. Additionally, regarding reduced C4 levels and RF positivity, given the relationship between serum C3 levels and ANCA-associated GN rather than serum C4 levels and the direct role of RF in cryoglobulinaemia, it was inferred that these laboratory subitems might be more likely to be associated with CryoVas than AAV [6,25].

The second consideration is whether the observed cases represent concurrence (e.g., overlap syndrome) or coincidental individual occurrences. Per the inclusion criteria, no patients with concomitant malignancies (e.g., monoclonal gammopathies), serious infectious diseases (e.g., chronic viral hepatitis), or autoantibody-related diseases other than AAV were included [1,2,6], thereby minimising confounding factors unrelated to AAV. However, as the mechanism by which CryoVas develops in patients with AAV remains unclear, the following hypotheses are proposed: patient #1 had RF and exhibited low C4 levels at diagnosis. RF may have played a central role in cryoglobulin formation, and ANCA itself, or antibodies other than ANCA generated by immune tolerance impairment due to AAV, may have bound to RF to promote cryoglobulin production. Therefore, patient #1 could be classified as having concurrent AAV and CryoVas because cryoglobulin production might be reasonably inferred. Conversely, patient #2 was RF-negative and had normal C4 levels. Therefore, patient #2 was diagnosed with a coincidental individual occurrence of AAV and CryoVas, since no relationship between the two diseases could be inferred.

The third consideration addresses the need for differential diagnosis between concurrent and coincidental occurrence of AAV and CryoVas in patients with both conditions. This distinction is critical due to differences in treatment strategies, particularly for severe cases. In terms of therapeutic strategies for severe AAV (MPA and GPA), a severe case of MPA and GPA is currently defined as the following cases: diffuse alveolar haemorrhage, rapidly progressive GN (RPGN), central nervous system involvement, peripheral neuropathy, myocarditis, mesenteric ischaemia, and digital ischaemic necrosis [26]. A combination of high-dose glucocorticoids with either rituximab or cyclophosphamide is recommended as the first line [26,27]. Conversely, no consensus exists for severe CryoVas; treatment typically focuses on underlying conditions (e.g., chronic viral hepatitis or haematologic malignancies) and general immunosuppression tailored to affected organs [28,29]. In this study, the two patients with CryoVas and AAV, lacking chronic viral hepatitis or haematologic malignancies, received high-dose glucocorticoids and rituximab for histologically confirmed RPGN associated with MPA rather than CryoVas. Their lung lesions were not severe enough to warrant rituximab as induction therapy. Excluding renal and pulmonary involvement, peripheral neuropathy might have guided treatment decisions: if attributed to AAV, rituximab would be prioritized; if linked to CryoVas, additional options like apheresis or plasma exchange might be considered [30,31]. Considering these circumstances, we believe that in patients classified as having CryoVas alongside AAV and in those with evident symptoms of major organ involvement, biopsy of the affected organ should be actively considered when clinically feasible.

The final consideration is the potential for false-positive or false-negative cryoglobulin test results due to multiple factors: i) if blood collection and sample processing are not maintained at 37°C, cryoprecipitate may form during clotting; ii) inadequate storage of serum at the proper temperature (4°C) after centrifugation may affect cryoprecipitate formation and concentration; iii) serum turbidity, caused by lipemia or fibrin formation during clotting, can interfere with result interpretation; and iv) the presence of immune complexes, which may form cryoglobulins due to inflammatory or infectious diseases, can also lead to inaccurate results [32]. Additionally, in clinical practice, because cryoglobulin testing relies on visual inspection rather than sensitive methods such as spectrophotometry [33], its sensitivity may be reduced when cryoglobulin concentrations are low, thereby increasing the risk of false negatives. However, as repeated cryoglobulinaemia was accepted as cryoglobulin-positive in this study, the likelihood of false results was likely minimised.

This study has several advantages: i) it is the first to quantify the rate of positive cryoglobulin test results and the concurrence of AAV and CryoVas in a cohort of patients with AAV; ii) it also provides a framework for considering concurrent versus coincidental occurrences of these conditions; and iii) it excludes the potential causes of cryoglobulinaemia, such as chronic viral hepatitis or haematologic malignancies, enhancing the focus on AAV-related findings, though not comprehensively. However, several limitations should be acknowledged. First, although the AAV cohort included in this study was the largest and most well-established cohort in Korea, the single-centre design limited patient numbers and institutional diversity. Second, although data collection was conducted prospectively, retrospective analyses introduced risks of missing or inconsistent data. Third, cryoglobulin retesting was performed only in patients with cryoglobulin positivity at diagnosis, potentially missing subsequent positivity in initially negative patients during follow-up. Fourth, the lack of standardised procedures in cryoglobulin testing might have contributed to the insufficient confirmation of the concurrence of AAV and CryoVas. Finally, a nerve biopsy was not performed in patient #1, who presented with symptoms of peripheral neuropathy, as a nerve biopsy would have provided useful information for differentiating between AAV and CryoVas.

In conclusion, this study demonstrated that the incidence rate of cryoglobulinaemia and CryoVas in patients with AAV without chronic viral hepatitis or haematologic malignancies is 1.5%. Although evidence is insufficient to strongly recommend routine cryoglobulin testing for all patients diagnosed with AAV, given the several differences in clinical features, disease progression, prognosis, and treatment modalities between AAV and CryoVas, we would recommend a cryoglobulin test at the time of AAV diagnosis and active biopsy of organs affected by vasculitis, if possible. This is particularly encouraged in patients presenting with purpuric skin lesions, constitutional (febrile) symptoms, and articular manifestations.

KEY MESSAGE

1. Cryoglobulin was detected in the sera of two of the 136 patients with AAV, both exhibiting repeated cryoglobulinaemia, and these patients were classified as having CryoVas alongside AAV, yielding a detection rate of cryoglobulin and an incidence of CryoVas of 1.5%.

2. All patients classified as having concomitant CryoVas presented with purpuric skin lesions, constitutional (febrile) symptoms, and articular manifestations.

3. Neurological manifestations and CryoVas-related laboratory findings varied between the two patients.

Notes

CRedit authorship contributions

J.Y. Whang: Conceptualization, Methodology, Resources, Investigation, Data curation, Formal analysis, Software, Writing - original draft, Writing - review & editing, Visualization, Project administration; J.W. Ha: Conceptualization, Methodology, Resources, Investigation, Data curation, Formal analysis, Software, Writing - original draft, Writing - review & editing, Visualization, Project administration; J. Chung: Methodology, Investigation, Data curation, Formal analysis, Software, Writing - review & editing; Y.B. Park: Conceptualization, Resources, Investigation, Validation, Writing - review & editing; J. Song: Conceptualization, Resources, Investigation, Validation, Writing - review & editing; Y. Park: Conceptualization, Methodology, Resources, Investigation, Data curation, Formal analysis, Software, Writing - original draft, Writing - review & editing, Visualization, Supervision, Project administration; S.W. Lee: Conceptualization, Methodology, Resources, Investigation, Data curation, Formal analysis, Software, Writing - original draft, Writing - review & editing, Visualization, Supervision, Project administration, Funding acquisition

Conflicts of interest

The authors disclose no conflicts.

Funding

This study was funded by Eisai Korea Inc. Seoul, Republic of Korea (4-2024-0700), and Yuhan Corporation, Seoul, Republic of Korea, as part of their “2024 Investigator Initiated Translation Research Program” (4-2025-0044). The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication.

Figure 1

Patients’ selection. AAV, antineutrophil cytoplasmic antibody-associated vasculitis.

Table 1

Characteristics of patients with AAV having the results of cryoglobulin tests at diagnosis (n = 136)

Variable at diagnosis	Values
Demographic data
Age (years)	61.0 (50.0–69.0)
Sex
Male	56 (41.2)
Female	80 (58.8)
BMI (kg/m²)	22.6 (20.8–24.8)
Ex-smoker	2 (1.5)
AAV subtype
MPA	75 (55.1)
GPA	31 (22.8)
EGPA	30 (22.1)
ANCA type and positivity
MPO-ANCA (or P-ANCA) positivity	101 (74.3)
PR3-ANCA (or C-ANCA) positivity	20 (14.7)
AAV-specific indices
BVAS	11.0 (6.0–17.0)
FFS	1.0 (0–2.0)
Systemic manifestations based on the items of BVAS
General manifestation	46 (33.8)
Cutaneous manifestation	23 (16.9)
Mucous membranous and ocular manifestation	9 (6.6)
Otorhinolaryngological manifestation	67 (49.3)
Pulmonary manifestation	96 (70.6)
Cardiovascular manifestation	15 (11.0)
Abdominal manifestation	1 (0.7)
Renal manifestation	75 (55.1)
Nervous system manifestation	42 (30.9)
Laboratory results
White blood cell count (/mm³)	8,845.0 (6,715.0–12,270.0)
Haemoglobin (g/dL)	12.0 (10.0–13.6)
Platelet count (× 1,000/mm³)	304.5 (216.8–387.8)
Blood urea nitrogen (mg/dL)	18.2 (13.7–29.9)
Serum creatinine (mg/dL)	0.8 (0.6–1.6)
Serum total protein (g/dL)	6.8 (6.4–7.4)
Serum albumin (g/dL)	4.0 (3.3–4.4)
Acute phase reactants
ESR (mm/hr)	58.0 (19.0–96.0)
CRP (mg/L)	8.5 (1.4–48.2)
Cryoglobulin	2 (1.5)

Table 2

The classification criteria for cryoglobulinaemic vasculitis

	Patients #1	Patient #2
Satisfied if at least two of the three items (questionnaire, clinical, laboratory) are positive	Satisfied	Satisfied
The patient must be positive for serum cryoglobulin in at least 2 determinations at > 12 weeks interval	Yes	Yes
(1) Questionnaire item: at least two out of the following
Do you remember one or more episodes of small red spots on your skin, particularly involving the lower limbs?	Yes	Yes
Have you ever had red spots on your lower extremities which leave a brownish colour after their disappearance?	Yes	Yes
Has a doctor ever told you that you have viral hepatitis?
(2) Clinical item: at least three out of the following four (present or past)
Constitutional symptoms
Fatigue	Yes	Yes
Low grade fever (37–37.9°C, > 10 days, no cause)
Fever (> 38°C, no cause)	Yes	Yes
Fibromyalgia
Articular involvement
Arthralgias	Yes	Yes
Arthritis
Vascular involvement
Purpura	Yes	Yes
Skin ulcers
Necrotising vasculitis
Hyperviscosity syndrome
Raynaud’ phenomenon
Neurologic involvement
Peripheral neuropathy	Yes
Cranial nerve involvement
Vasculitic CNS involvement
(3) Laboratory items: at least two out of the following three (present)
Reduced serum C4	Yes
Positive serum rheumatoid factor	Yes
Positive serum M component

REFERENCES

1. Roccatello D, Saadoun D, Ramos-Casals M, et al. Cryoglobulinaemia. Nat Rev Dis Primers 2018;4:11.

2. Ramos-Casals M, Stone JH, Cid MC, Bosch X. The cryoglobulinaemias. Lancet 2012;379:348–360.

3. Stoyanov A, Toong C, Kong Y, Chen R, Urriola N. Serum protein electrophoresis and rheumatoid factor analysis is an effective screening strategy for cryoglobulinaemia. Pathology 2023;55:391–396.

4. Silva F, Pinto C, Barbosa A, Borges T, Dias C, Almeida J. New insights in cryoglobulinemic vasculitis. J Autoimmun 2019;105:102313.

5. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013;65:1–11.

6. De Vita S, Soldano F, Isola M, et al. Preliminary classification criteria for the cryoglobulinaemic vasculitis. Ann Rheum Dis 2011;70:1183–1190.

7. Quartuccio L, Isola M, Corazza L, et al. Validation of the classification criteria for cryoglobulinaemic vasculitis. Rheumatology (Oxford) 2014;53:2209–2213.

8. Kronbichler A, Lee KH, Denicolò S, et al. Immunopathogenesis of ANCA-associated vasculitis. Int J Mol Sci 2020;21:7319.

9. Kolopp-Sarda MN, Miossec P. Cryoglobulinemic vasculitis: pathophysiological mechanisms and diagnosis. Curr Opin Rheumatol 2021;33:1–7.

10. Watts R, Lane S, Hanslik T, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 2007;66:222–227.

11. Suppiah R, Robson JC, Grayson PC, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis. Ann Rheum Dis 2022;81:321–326.

12. Robson JC, Grayson PC, Ponte C, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. Arthritis Rheumatol 2022;74:393–399.

13. Grayson PC, Ponte C, Suppiah R, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis. Ann Rheum Dis 2022;81:309–314.

14. Pyo JY, Lee LE, Park YB, Lee SW. Comparison of the 2022 ACR/EULAR classification criteria for antineutrophil cytoplasmic antibody-associated vasculitis with previous criteria. Yonsei Med J 2023;64:11–17.

15. Yang X, Jiao C, Liu X, Zhang Y, Zhou H, Wang Y. Coexistence of cryoglobulinemia and ANCA-associated vasculitis in a chronic brucellosis patient -a case report and literature review. BMC Infect Dis 2023;23:272.

16. Lamprecht P, Gutzeit O, Csernok E, et al. Prevalence of ANCA in mixed cryoglobulinemia and chronic hepatitis C virus infection. Clin Exp Rheumatol 2003;21:S89–S94.

17. Bossuyt X, Cohen Tervaert JW, Arimura Y, et al. Position paper: revised 2017 International Consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nat Rev Rheumatol 2017;13:683–692.

18. Moiseev S, Cohen Tervaert JW, Arimura Y, et al. 2020 International Consensus on ANCA testing beyond systemic vasculitis. Autoimmun Rev 2020;19:102618.

19. Mukhtyar C, Lee R, Brown D, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 2009;68:1827–1832.

20. Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Toumelin PL. The five-factor score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 2011;90:19–27.

21. Graf J, Imboden J. Vasculitis and peripheral neuropathy. Curr Opin Rheumatol 2019;31:40–45.

22. Soulages A, Maisonobe T, Auzou P, et al. Peripheral neuropathy and livedoid vasculopathy. J Neurol 2022;269:3779–3788.

23. Choi SE, Lee SB, Pyo JY, et al. Renal histopathological predictors of end-stage kidney disease in ANCA-associated vasculitis with glomerulonephritis: a single-centre study in Korea. Sci Rep 2023;13:14850.

24. Alpers CE, Smith KD. Cryoglobulinemia and renal disease. Curr Opin Nephrol Hypertens 2008;17:243–249.

25. Hakroush S, Tampe D, Baier E, Kluge IA, Ströbel P, Tampe B. Intrarenal synthesis of complement C3 localized to distinct vascular compartments in ANCA-associated renal vasculitis. J Autoimmun 2022;133:102924.

26. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol 2021;73:1366–1383.

27. Casal Moura M, Gauckler P, Anders HJ, et al. Management of antineutrophil cytoplasmic antibody-associated vasculitis with glomerulonephritis as proposed by the ACR 2021, EULAR 2022 and KDIGO 2021 guidelines/recommendations. Nephrol Dial Transplant 2023;38:2637–2651.

28. Nelveg-Kristensen KE, Paterson A, Willcocks LC. Cryoglobulinaemic vasculitis diagnostic and treatment recommendations. Rheumatology (Oxford). 2021;60:iii39–iii42.

29. Moretti M, Ferro F, Baldini C, Mosca M, Talarico R. Cryoglobulinemic vasculitis: a 2023 update. Curr Opin Rheumatol 2024;36:27–34.

30. Cai FZ, Ahern M, Smith M. Treatment of cryoglobulinemia associated peripheral neuropathy with rituximab. J Rheumatol 2006;33:1197–1198.

31. Rockx MA, Clark WF. Plasma exchange for treating cryoglobulinemia: a descriptive analysis. Transfus Apher Sci 2010;42:247–251.

32. Motyckova G, Murali M. Laboratory testing for cryoglobulins. Am J Hematol 2011;86:500–502.

33. Codes-Méndez H, Jeria S, Park HS, et al. Clinical and serological profiles in cryoglobulinemia: analysis of isotypes and etiologies. J Clin Med 2024;13:6069.